Expert Outlook: Sarepta Therapeutics Through The Eyes Of 25 Analysts
Portfolio Pulse from Benzinga Insights
Sarepta Therapeutics (NASDAQ:SRPT) has received mixed ratings from 25 analysts over the past three months, with a majority being somewhat bullish. The average 12-month price target has increased to $182.8, with a high estimate of $235.00 and a low estimate of $128.00. Analysts have recently adjusted their ratings and price targets, reflecting their evolving perspectives on the company's performance.
July 01, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sarepta Therapeutics has received a mix of bullish and somewhat bullish ratings from analysts, with an increase in the average 12-month price target to $182.8. This reflects positive sentiment and expectations for the company's future performance.
The majority of analysts have given somewhat bullish ratings, and the average price target has increased, indicating positive sentiment and expectations for future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100